Mersana Therapeutics, Inc.
MRSN
$0.3659
$0.00982.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.01M | 40.50M | 34.84M | 29.94M | 38.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.01M | 40.50M | 34.84M | 29.94M | 38.30M |
| Cost of Revenue | 72.68M | 73.02M | 72.23M | 87.96M | 119.68M |
| Gross Profit | -38.67M | -32.52M | -37.39M | -58.02M | -81.38M |
| SG&A Expenses | 38.18M | 40.81M | 42.06M | 45.09M | 52.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 110.85M | 113.83M | 114.29M | 133.05M | 172.46M |
| Operating Income | -76.85M | -73.34M | -79.45M | -103.11M | -134.16M |
| Income Before Tax | -73.59M | -68.77M | -74.20M | -104.77M | -134.81M |
| Income Tax Expenses | 418.00K | 418.00K | 418.00K | -- | -- |
| Earnings from Continuing Operations | -74.01 | -69.19 | -74.62 | -104.77 | -134.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.01M | -69.19M | -74.62M | -104.77M | -134.81M |
| EBIT | -76.85M | -73.34M | -79.45M | -103.11M | -134.16M |
| EBITDA | -75.33M | -71.71M | -77.78M | -101.41M | -132.54M |
| EPS Basic | -0.60 | -0.57 | -0.61 | -0.86 | -1.14 |
| Normalized Basic EPS | -0.37 | -0.35 | -0.38 | -0.50 | -0.67 |
| EPS Diluted | -0.60 | -0.57 | -0.61 | -0.86 | -1.14 |
| Normalized Diluted EPS | -0.37 | -0.35 | -0.38 | -0.50 | -0.67 |
| Average Basic Shares Outstanding | 493.19M | 490.15M | 487.20M | 485.00M | 478.17M |
| Average Diluted Shares Outstanding | 493.19M | 490.15M | 487.20M | 485.00M | 478.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |